JNJ-74856665

N/A

Report date: 2024/12/04 13:50:30
NME

Base Information

Drug NameJNJ-74856665
Drug Alias NameJNJ-6665JNJ-74856665
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUkraineTaiwan +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJanssen Research & Development Llc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMyelodysplastic SyndromesProstatic Neoplasms, Castration-Resistant +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A